Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Itacitinib
Biological: Chimeric antigen receptor (CAR) T-cell therapy

First Posted Date: 2023-03-07

Last Posted Date: 2025-06-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT05757219

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Phase 2

Recruiting

Conditions: Metastatic Prostate Cancer
Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Enzalutamide
Drug: Apalutamide
Drug: Sipuleucel-T

First Posted Date: 2023-03-02

Last Posted Date: 2025-05-15

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 26

Registration Number: NCT05751941

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV/AIDS

Not Applicable

Recruiting

Conditions: Smoking Cessation
HIV

Interventions: Behavioral: Smartphone-delivered Automated Messaging
Drug: Nicotine patch
Behavioral: Brief Advice to Quit and Smoking Cessation Self Help Materials
Behavioral: Diet Assessment

First Posted Date: 2023-02-27

Last Posted Date: 2025-06-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 800

Registration Number: NCT05746442

Locations: 🇰🇭
National AIDS Authority, Phnom Penh, Cambodia
🇰🇭
National Center for HIV/AIDS, Dermatology and STD, Phnom Penh, Cambodia
🇰🇭
National Institute of Public Health, Phnom Penh, Cambodia

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Phase 2

Recruiting

Conditions: Myelodysplastic Syndromes
Myeloproliferative Neoplasm
Anemia

Interventions: Drug: Luspatercept

First Posted Date: 2023-02-17

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 70

Registration Number: NCT05732961

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Early Phase 1

Completed

Conditions: Metastatic Melanoma
Metastasis to Brain

Interventions: Drug: Nivolumab + Relatlimab
Drug: Nivolumab
Procedure: Standard of Care Craniotomy
Drug: Ipilimumab

First Posted Date: 2023-01-30

Last Posted Date: 2025-06-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1

Registration Number: NCT05704933

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
Triple Negative Breast Cancer Malignancies
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: PRGN-3007

First Posted Date: 2023-01-23

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT05694364

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Active, not recruiting

Conditions: Chronic Pancreatitis
FAP
Pancreatic Ductal Adenocarcinoma
Genetic Pancreatitis
Pancreatic Cyst
Fatty Pancreas
Familial Atypical Multiple Mole-Melanoma
Peutz-Jeghers Syndrome
Ataxia Telangiectasia
Genetic Pancreatic Cancer

First Posted Date: 2023-01-20

Last Posted Date: 2025-07-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 317

Registration Number: NCT05692596

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Recruiting

Conditions: Pancreatic Cancer

First Posted Date: 2023-01-18

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 125

Registration Number: NCT05687188

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions: Biological: Tumor-infiltrating Lymphocytes (TIL)
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating Lymphocyte Therapy
Drug: Interleukin-2 (IL2)

First Posted Date: 2023-01-12

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05681780

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

Not Applicable

Recruiting

Conditions: Human Papilloma Virus (HPV) Vaccine

First Posted Date: 2023-01-10

Last Posted Date: 2025-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 564

Registration Number: NCT05677360

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy